SCWorx Corp.

SCWorx Corp. announced that the Nasdaq Hearings Panel has granted its request for reconsideration and approved the continued listing of its common stock on The Nasdaq Capital Market. The company has demonstrated compliance with Nasdaq's minimum bid price and publicly held shares requirements, leading to the reinstatement of trading on Nasdaq, which was suspended since April 14, 2026. This decision follows a private placement and a reverse stock split, which helped the company meet the listing standards. Trading will resume on a date to be scheduled by Nasdaq, with the company currently quoted on the OTCQB Venture Market.

SCWorx Corp. announced a two-year agreement with one of Massachusetts' largest integrated delivery networks (IDNs). Under the agreement, SCWorx will provide its proprietary healthcare data normalization, item master management, and supply chain data enrichment solutions. This partnership aims to improve the accuracy, consistency, and usability of critical supply chain information, supporting procurement optimization and data governance for the healthcare organization.

SCWorx Corp. announced a 1-for-12 reverse stock split of its common stock, effective August 3, 2026. This action is primarily intended to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. However, the company also faces non-compliance with other Nasdaq listing rules, including the market value of publicly held shares and minimum publicly held shares requirements, with no guarantee that the reverse split will prevent delisting or result in a sustained increase in stock price.

SCWorx Corp. announced it received a partial compliance letter from the Nasdaq Hearings Panel, confirming the completion of the first benchmark for its plan to regain continued listing on The Nasdaq Capital Market. The company still needs to achieve a closing bid price of at least $1.00 per share for a minimum of twenty consecutive trading days to fully comply with Nasdaq Listing Rule 5815(c)(4). SCWorx leadership emphasized that maintaining its Nasdaq listing remains a strategic priority.

SCWorx Corp. received a notice from Nasdaq indicating non-compliance with the minimum Market Value of Publicly Held Shares (MVPHS) requirement of $1 million. The company's MVPHS was below this threshold for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(5). SCWorx has a 180-day period, until January 20, 2027, to regain compliance. Failure to do so could lead to delisting, though the company can appeal such a decision.

SCWorx Corp. announced a new agreement with a prominent not-for-profit teaching hospital to provide data management and normalization services. These services will support the hospital's Workday ERP implementation by cleansing, standardizing, enriching, and optimizing its item master and supply chain data assets. The project aims to ensure data quality and consistency, reflecting the growing demand for specialized expertise in healthcare ERP transformations. This deal further expands SCWorx's customer portfolio, though financial terms were not disclosed.

SCWorx Corp. received a decision from a Nasdaq Hearings Panel granting its request to continue the listing of its common stock, which was suspended on April 14, 2026, for failing to meet the $1.00 minimum bid price rule. The continuation is conditional, requiring the company to obtain shareholder approval for a reverse stock split by July 22, 2026, effect the split by August 3, 2026, and demonstrate compliance with the $1.00 bid price for 20 consecutive trading days by August 28, 2026. Failure to meet these deadlines will result in delisting from Nasdaq, though the stock would continue to be quoted on OTC Markets.

SCWorx Corp. announced it has received a decision from the Nasdaq Hearings Panel granting its request to continue listing on The Nasdaq Stock Market, subject to specific conditions. The company's common stock was suspended on April 14, 2026, for not meeting the $1.00 minimum bid price rule. To regain compliance, SCWorx must obtain shareholder approval for a reverse stock split by July 22, 2026, effect the split by August 3, 2026, and demonstrate a closing bid price of $1.00 or more for 20 consecutive trading days by August 28, 2026. Failure to meet these deadlines will result in delisting, though the stock would continue to be quoted on OTC Markets.

SCWorx Corp. has filed its Definitive Proxy Statement for its Annual Meeting of Shareholders scheduled for July 22, 2026. Key proposals include the election of four directors, an advisory vote on executive compensation, and the ratification of Astra Audit & Advisory, LLC as the independent auditor. A significant proposal is the consideration of a reverse stock split (ranging from 1/1.5 to 1/10) to regain compliance with Nasdaq's minimum bid price rule, following its delisting from the Nasdaq Capital Market on April 14, 2026. The company is appealing this delisting and aims to demonstrate a plan for re-listing.

SCWorx Corp. reported a significant improvement in its financial performance for the first quarter of 2026, with net loss narrowing to $(173,767) or $(0.16) per share, compared to a net loss of $(476,303) or $(3.71) per share in the prior year. Revenue saw a modest increase of 3.4% to $744,899, while gross profit more than doubled to $374,109. The company also implemented a 1-for-15 reverse stock split in April 2026, which is reflected in the reported figures.